Australia markets closed

Orphazyme A/S (OZYMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.1500-0.2800 (-6.32%)
At close: 11:36AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.4300
Open4.1500
BidN/A x N/A
AskN/A x N/A
Day's range4.1500 - 4.1500
52-week range3.8200 - 18.1000
Volume100
Avg. volume1,655
Market cap145.052M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)-3.9880
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Modified long-term share-based incentive program for 2021

    Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the “LTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the

  • GlobeNewswire

    Orphazyme provides regulatory and financial updates

    Orphazyme A/SCompany announcement No. 22/2021Company Registration No. 32266355 Copenhagen – October 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC). The company also announces that it now expects to end 2021 with a cash position of no les

  • PR Newswire

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Orphazyme A/S and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ: ORPH) for violations of the federal securities laws.